IP Library › Granted Patent US 9,708,608
Granted Patent B2
US 9,708,608 · App. 14/431,857 · Granted Jul 18, 2017

Methods for producing a population of pancreatic beta-cells

Inventors: Patrick Collombat (Nice, FR); Keith Al-Hasani (Nice, FR); Monica Courtney (Nice, FR); Nouha Ben-Ohtman (Nice, FR); Elisabet Gjernes (Nice, FR); Ahmed Mansouri (Goettingen, DE)
Assignees: Institut National de la Sante et de la Recherche Medicale (INSERM); Centre National de la Recherche Scientific (CNRS); Universite Nice Sophia Antipolis
C12N15/113A01K67/0276A61K31/00A61K31/197A61K31/713A61K45/06C12N5/0676A01K2217/075A01K2217/206A01K2227/105A01K2267/0362C12N2310/11C12N2310/12C12N2310/14C12N2320/30C12N2501/60C12N2501/845
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,708,608
App. No.
14/431,857
Granted
Jul 18, 2017
Kind
B2
Abstract

The present invention relates to an in vitro or ex vivo method for producing a population of pancreatic beta-cells, comprising the step of inhibiting the expression or the activity of Arx in a population of pancreatic alpha-cells. The present invention also relates to method for inducing the conversion of pancreatic alpha-cells in pancreatic beta-cells in a patient in need thereof.

Claims (9)

1. An in vitro or ex vivo method for producing a population of pancreatic beta-cells, comprising the steps of:

inhibiting the expression of Aristaless related homeodomain protein (Arx) by contacting a population of pancreatic alpha-cells with Gamma-Amino Butyric Acid (GABA) or a GABA receptor agonist in an amount sufficient to inhibit expression of Arx and induce conversion of the pancreatic alpha-cells to pancreatic beta-cells; and

confirming that a population of pancreatic beta-cells suitable for administration to a subject is produced by detecting at least one of insulin production upon glucose stimulation, a beta-cell surface antigen, a beta-cell transcription factor, or a beta-cell ultrastructure.

2. The method according to claim 1 , with the proviso that the expression of Arx is not inhibited by using a Pax-4 polypeptide or a nucleic acid encoding Pax-4 gene or a vector comprising a nucleic acid encoding Pax-4 gene.

3. The method according to claim 1 , wherein the GABA receptor agonist is selected from the group consisting of thiopental, thiamylal, pentobarbital, secobarbital, hexobarbital, butobarbital, amobarbital, barbital, mephobarbital, phenobarbital, primidone, midazolam, triazolam, lometazepam, flutazolam, nitrazepam, fluritrazepam, nimetazepam, diazepam, medazepam, oxazolam, prazeam, tofisopam, rilmazafonoe, lorazepam, temazepam, oxazepam, fluidazepam, chlordiazepoxide, cloxazolam, flutoprazepam, alprazolam, estazolam, bromazepam, flurazepam, clorazepate potassium, haloxazolam, ethyl loflazepate, qazepam, clonazepam, mexazolam, etizolam, brotizolam, clotizaepam, propofol, fospropofol, zolpidem, zopiclone, and exzopiclone.

4. The method according to claim 1 wherein the population of pancreatic alpha-cells is a population of adult pancreatic alpha-cells.

5. The method of claim 1 , wherein said beta-cell surface antigen is glucose transporter 2 (GLUT2).

6. The method of claim 1 , wherein said beta-cell transcription factor is selected from the group consisting of Pancreatic duodenal homeobox 1 (Pdx 1), NK6 Homeobox 1 (Nkx6.1), MAF transcription factor A (MafA), and Paired Box 4 (Pax4).

7. The method of claim 1 , wherein said beta-cell ultrastructure is detected by electron microscopy.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 13, 2015
From: COLLOMBAT, PATRICK; AL-HASANI, KEITH; COURTNEY, MONICA; BEN-OHTMAN, NOUHA; GJERNES, ELISABET; MANSOURI, AHMED
To: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE); CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS); UNIVERSITE NICE SOPHIA ANTIPOLIS
Reel/Frame 035389/0700 →
Priority Claims (1)
EP 12306172 · Sep 27, 2012 · regional
Continuity (1)
Related Publication 20150240235A1 · Aug 27, 2015